EG 427 highlights at ASGCT major advances made with its HERMES platform in neurology using versatile non-replicative herpes vectors
May 13, 2025- Data highlights advantages of single, non-replicative HSV-1 (nrHSV-1) vector hosting two transgenes with independent expression kinetics
- Vectors also show high transduction rate of neurons in the CNS at very low doses and can be efficiently distributed to connected brain regions via retrograde transfer
- Supports pipeline growth leveraging new vector attributes to address genetic medicine challenges in highly prevalent pathologies
Read the full Press release in English or in French
Recent posts
Significant milestone reached for EG 427 with first patient treated with EG110A, first non-replicative herpes vector based genetic medicine for the treatment of neurogenic bladder
